Dr. Amy Kao joined TVM Capital in April 2023.
Before TVM, Amy was at Oxford Science Enterprises, an early stage venture funding & building investment company focusing on healthtech. Amy brings rich experiences in strategy transactions & innovation from her previous roles with EY Global and Merck KGaA as well as hands-on operational experience having been Chief of Staff at Neu Health, a digital Parkinson’s and Dementia platform.
Her academic work in the gut-brain axis has been published in Nature’s Translational Psychiatry and other high-impact journals, including Schizophrenia Research, Neuropharmacology, and Psychoneuroendocrinology.
Amy holds a DPhil in neuroscience from the University of Oxford.